Ironwood Pharmaceuticals Inc
Închisă
SectorSănătate
4.3 5.39
Rezumat
Modificarea prețului
24h
Minim
4.16
Maxim
4.34
Venit | 11M 51M |
|---|---|
Vânzări | 6.5M 113M |
P/E Medie Sector | 5.468 57.002 |
EPS | 0.31 |
Marjă de profit | 45.374 |
Angajați | 100 |
EBITDA | 6.2M 81M |
Următoarele câștiguri | 9 nov. 2026 |
|---|
Capitalizare de piață | -14M 714M |
|---|---|
Deschiderea anterioară | -1.09 |
Închiderea anterioară | 4.3 |
Sentimentul știrilor
By Acuity
50%
50%
163 / 340 Clasament în Healthcare
Ironwood Pharmaceuticals Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Ironwood Pharmaceuticals Inc Așteptări
Sentiment
By Acuity
163 / 340 Clasament în Sănătate
Sentimentul știrilor
Neutral
Volatilitate
Sub medie
Volumul știrilor (RCV)
Sub medie
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
Cheltuieli cu dobânzile pe datorie
EBITDA
Profit operațional
$
Despre Ironwood Pharmaceuticals Inc
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
